This is a working overview of NMN, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-05. Anything still debated is marked as such rather than presented as settled.
NMN is a polar, water-soluble nucleotide. In solid form it is usually a white to off-white powder. The compound is sensitive to heat, light, moisture, and extremes of pH, and aqueous solutions tend to degrade faster than dry material. Recommended storage for research samples is typically -20 °C or below in a sealed, desiccated container protected from light. Repeated freeze-thaw cycles should be avoided, and these handling practices help maintain identity and purity during laboratory use.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Quality control for NMN typically checks identity, assay purity, residual solvents, heavy metals, and microbial limits, depending on the intended use and market. A certificate of analysis may report appearance, solubility, water content, and storage recommendations. Independent verification can compare chromatographic retention time and mass spectrum against a certified reference standard. Regulatory expectations differ between research chemicals, dietary ingredients, and pharmaceutical products. Impurity profiles and stability data are often requested for product approval, and open questions remain about how best to standardize NMN measurements across laboratories.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for solid free acid or salt forms |
| Solubility | Freely soluble in water | Polar nucleotide; limited solubility in nonpolar solvents |
| Typical storage | -20 °C or below | Desiccated, protected from light |
| Common analytical method | LC-MS or HPLC-UV | Used for identity and purity assessment |
| Common synonyms | Nicotinamide ribonucleotide; beta-NMN | NMN is the usual abbreviation |
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally stored cold, often at minus twenty degrees Celsius or lower, in a desiccated container protected from light. Aqueous solutions tend to be less stable than dry powder because hydrolysis and dephosphorylation can occur, potentially forming nicotinamide riboside or other degradation products. Stress studies may expose samples to heat, acid, base, oxidation, and strong light to identify likely degradation pathways. Results from such studies help define shelf life and handling recommendations, though exact stability depends on formulation and packaging.
Quality control for NMN materials typically includes identity, assay, purity, and impurity profiling. Tests may cover residual solvents, heavy metals, microbial limits, and water content, depending on the intended use and local rules. Impurity profiles can include related substances such as nicotinamide, nicotinamide riboside, and NAD+, which may form during synthesis or storage. Because commercial NMN can be offered as different salts or hydrate forms, a certificate of analysis should state the form and the analytical methods used. Independent verification is relevant because supplement markets vary in testing requirements and enforcement.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
== Nutritional deficiencies (260–269) == 260 Kwashiorkor 261 Nutritional marasmus 262 Other severe protein–calorie malnutrition 263 Other and unspecified protein–calorie malnutrition 264 Vitamin A deficiency 264.0 With conjunctival xerosis 264.1 With conjunctival xerosis and Bitot's spot 264.2 With corneal xerosis 264.3 With corneal ulceration and xerosis 264.4 With keratomalacia 264.5 With night blindness 264.6 With xerophthalmic scars of cornea 264.7 Other ocular manifestations of vitamin A deficiency 264.8 Other manifestations of vitamin A deficiency 264.9 Unspecified vitamin A deficiency 265 Thiamine and niacin deficiency states 265.0 Beriberi 265.1 Other and unspecified manifestations of thiamine deficiency Wernicke's encephalopathy 265.2 Pellagra 266 Deficiency of B-complex components 266.0 Ariboflavinosis 266.2 B12 deficiency w/o anemia 267 Ascorbic acid deficiency 268 Vitamin D deficiency 269 Other nutritional deficiencies 269.0 Deficiency of vitamin K 269.1 Deficiency of other vitamins 269.2 Unspecified vitamin deficiency 269.3 Mineral deficiency, not elsewhere classified
=== Skeletal muscle === In skeletal muscle, contraction is stimulated by electrical impulses transmitted by the motor nerves. Cardiac and smooth muscle contractions are stimulated by internal pacemaker cells which regularly contract, and propagate contractions to other muscle cells they are in contact with. All skeletal muscle and many smooth muscle contractions are facilitated by the neurotransmitter acetylcholine.
Positron emission tomography imaging studies have reportedly found that tramadol levels are at least four-fold higher in the brain than in plasma. Conversely, brain levels of desmetramadol "only slowly approach those in plasma". The plasma protein binding of tramadol is only 4–20%; hence, almost all tramadol in circulation is free, thus bioactive.
Sources: en.wikipedia.org
=== Diabetes mellitus === Epinephrine signals early warning of the upcoming hypoglycemia. Beta blockers' inhibition on epinephrine's effect can somewhat exacerbate hypoglycemia by interfering with glycogenolysis and mask signs of hypoglycemia such as tachycardia, palpitations, diaphoresis, and tremors. Diligent blood glucose level monitoring is necessary for a patient with diabetes mellitus on beta blockers.
18-Methoxycoronaridine (18-MC; developmental code name MM-110), also known as zolunicant (INNTooltip International Nonproprietary Name), is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemists Upul K. Bandarage and Martin E. Kuehne from the University of Vermont. 18-MC was originally developed by Savant HWP and later acquired by MindMed in 2019 for development as a treatment for opioid use disorder. A Phase 1 trial in healthy volunteers was completed in 2022 with favorable safety and tolerability. Due to strategic reprioritization, MindMed discontinued active development of MM-110 in 2023 and has been seeking non-dilutive funding or partners to potentially restart the program; as of 2025 the program remains shelved. A separate Phase 2 trial in Brazil for cutaneous leishmaniasis (initiated 2017) has unknown status with no published results.
Pulmonary disease: Pathophysiology: Due to vascular congestion in the lung, the pulmonary artery (Figure 3) becomes dilated and can compress the aorta and the LRLN. Primary pulmonary hypertension Pulmonary emboli Malignancy (pulmonary, mediastinal) Autoimmune: Mixed connective tissue disease Notable case: A young female with a history of mixed connective tissue disease presented with hoarseness of voice and was found to have secondary pulmonary artery hypertension. This was causing right heart enlargement and therefore compression of the LRLN. Idiopathic
== Signs and symptoms == The lesion is usually painless. The usual appearance is of two excess tissue folds in alveolar vestibule/buccal sulcus, with the flange of the denture fitting in between the two folds. It may occur in either the maxillary or mandibular sulci, although the latter is more usual. Anterior locations are more common than posterior. Less commonly there may be a single fold, and the lesion may appear on the lingual surface of the mandibular alveolar ridge. The swelling is firm and fibrous, with a smooth, pink surface. The surface may also show ulceration or erythema. The size of the lesion varies from less than 1 cm to involving the entire length of the sulcus.
Sources: en.wikipedia.org
A member of parliament (MP) is the representative in parliament of the people who live in their electoral district. Members of parliament typically form parliamentary groups, sometimes called caucuses, with members of the same political party. In many countries with bicameral parliaments, this term refers only to members of the lower house since upper house members often have a different title. The terms member of congress (or congressperson) and deputy are equivalent terms used in other jurisdictions.
Beyond anthraquinones, X. parietina contains additional pigments, including carotenoids such as mutatoxanthin, which contribute to its photoprotective capabilities. The total carotenoid content in X. parietina can reach up to 94.7 mg/g dry weight, significantly higher than in some related species, indicating a strong investment in light protection mechanisms. Furthermore, the synthesis of anthraquinones in X. parietina is linked to its symbiotic relationship with Trebouxia algae—ribitol, a carbohydrate supplied by the photobiont, has been shown to significantly enhance parietin production when provided in culture.
==== Warp Drive Bio ==== In 2012, Verdine founded Warp Drive Bio with cofounders George Church and James Wells. The company maps the genomes of soil-dwelling microbes in the search for potential treatments for drug-resistant ailments. In 2013, Verdine became full-time CEO of Warp Drive Bio, then handed the CEO position to Lawrence Reid in 2016 in order to found two new startups, FogPharma and LifeMine.
Sources: en.wikipedia.org
Solid NMN is generally stored in a sealed container at -20 °C or below, protected from light and moisture. Some suppliers recommend a desiccant and inert gas. Aqueous solutions are less stable and are often prepared fresh.
Liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy are common identity tests. HPLC with ultraviolet detection can assess purity by peak area. Results are usually compared with a certified reference standard.
Degradation can reduce the amount of intact NMN and create related impurities. Storage conditions and handling therefore affect measured purity and experimental reproducibility. Stability data also inform labeling and shelf-life claims.
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.